Synthesis and Structure-Activity Relationships of Novel Nor-Seco

Nov 15, 2016 - (6) Gubnard, D.: Gubritte-Voaelein, F.: Potier, P. Acc. Chem. Res. .... o 6a: R=Ph .... 13038) and Indena, SpA is also gratefully ackno...
0 downloads 0 Views 579KB Size
515

J. Org. Chem. 1994,59, 515-517

Synthesis and Structure-Activity Relationships of Novel Nor-Seco Analogs of Taxol and Taxotere Iwao Ojima,*yt Ivana Fenoglio,? Young Hoon Park,? Chung-Ming Sun: Giovanni Appendino,t Paula Pera,l and Ralph J. Bernackil Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, Dipartimento di Scienza e Tecnologia del Farmaco, Universith di Torino, 10125 Torino, Italy, and Department of Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263 Received November 15, 199P

Summary: Novel nor-seco analogs of taxol and taxotere are synthesized from 14-hydroxy-10-deacety1baccatinI11 through periodic acid oxidation and NaBH3CN reduction, followed by coupling with the C-13 side chain precursors using a highly efficient P-lactam synthon method. The new reduced structure analogs show muted cytotoxicity aganist human cancer cell lines compared with taxol but still retain a certain level of activity despite the destruction of the A ring. Taxol isolated from the bark of Taxus brevifolia is currently considered one of the most exciting leads in cancer chemotherapy.14 Taxotere, a semisynthetic analog, also has shown great Taxol possesses high cytotoxicityand strong antitumor activity against different cancers which have not been effectivelytreated by existing antitumor drugs.lOJ1 Taxol was approved by the FDA in late 1992 for the treatment of advanced ovarian cancer and is currently in phase I1and I11 clinical trials for breast cancer and lung cancers.12 Taxotere is currently in phase I1 and I11 clinical trials for different types of cancers in the United States, Europe, and J a ~ a n . ~ J ~ Studies on the structure-activity relationships (SAR) of taxol and taxotere have disclosed the essential role of the N-acylphenylisoserine moiety at C-13 as well as the oxetane ring (D-ring) for their strong anticancer activity.6Jb16 However, little is known of the SAR of the A and B rings of the baccatin framework. It is very important t

State University of New York at Stony Brook.

UniversitA di Torino. Park Cancer Institute. Abstract published in Advance ACS Abstracts, January 15, 1994. (1)Wani, M. C.; Taylor, H. L.; Wall,M. E.; Coggon, P.; McPhail, A. T. J.Am. Chem. SOC. 1971,93, 2325. (2) (a) Kingston, D. G. I.; Molinero, A. A.; Rimoldi, J. M. Prog. Chem. Org. Nat. Prod. 1993, 61, 1. (b) Suffness, M. In Annual Reports in Medicinal Chemistry, Bristol, J. A., Ed.; Academic Press: San Diego, 1993; Vol. 28, pp 305-314. (3) Rowinsky, E. K.; Cazenave, L. C.; Donehower,R. C. J. Natl. Cancer Inst. 1990.82.1247. (4)ko&sky, E. K.; Onetto, N.; Canetta, R. M.; Arbuck, S.G. Semin. Oncol. 1992, 19, 646. (5) Colin, M.; Gubnard, D.; Gubritte-Voegelein,F.; Potier, P. Eur. Pat. Appl. 1988, E P 253,738 Chem. Abstr. 1988,109, 22762~. (6) Gubnard, D.: Gubritte-Voaelein, F.: Potier, P. Acc. Chem. Res. 1993, 1 Roswell

~

26,160. (7) Lavelle,F.;Fizamers, C.; Gubritte-Vogelein,F.;Gubnard,D.;Potier, P. Proc. Am. Assoc. Cancer Res. 1989, 30,566.

(8) Bissery, M. C.; Gubritte-Vogelein, F.; Gubnard, D.;Lavelle,F. Cancer Res. 1991, 51, 4845. (9) Ravdin, P. M. In Stony Brook Symposium on Taxol and TaxotBre; Stony Brook, New York, , May 14-15, 1993; Abstracts p 18. (10) Shiff, P.; Fant, J.; Horwitz, S.3. Nature 1979,277,6652. (11) Horwitz,S. B. InStony BrookSymposiumon Taxoland Tarotare; Stony Brook, New York, May 14-15,1993; Abstracts p 23. (12) Seidman, A. D. In Stony Brook Symposium on Taxol and Tarotbe; Stony Brook, New York, May 14-15,1993; Abatracta p 14. (13) Burris, H.; Irwin, R.; Kuhn, J.; Kalter, L.; Smith, D.; Shafer, D.; Rodoriguez, G.; Gueiss, G.; Eckardt, J.; Vreeland, F.; Bayssas, M.; Von Hoff, D. Proc. Am. SOC. Clin. Oncol. 1992, 11, 369. (14) Kingston, D. G. I. Pharmac. Ther. 1991,52,1 and references cited therein.

to clarifythe minimum structural requirements for taxanes to exhibit anticancer activity by looking at simplified structure analogs of taxol. Along this line, we have investigated the role of the A ring by synthesizing novel nor-seco analogs of taxol and taxotere in which the A ring is cleaved but the B-D rings are retained. The novel nor-seco baccatin 3 was synthesized in 92% yield through oxidative cleavage of the A ring of 14-0hydroxy-10-deacetylbaccatinI11 (14-OH-DAB, 1) with periodic acid (eq 1). The new baccatin 1 was recently

HO

1

2

3

(92%)

isolated from the needles and other parts of Taxus wallichiana ZUCC.'~J~ It should be noted that this oxidative cleavage is realized because of the presence of the hydroxyl group at C-14, Le., this type cleavage is impossible for the usual 10-deacetylbaccatin I11 (DAB). The oxidative cleavage of 1 introduces a carbonyl to C-1 first, giving 2, which immediately reacts with the hydroxyl group at C-10 in situ to form the hemiacetal 3 (eq 1). The hydroxyl group of 3 at C-7 was selectively protected as triethylsilyl (TES) ether to give 7-TES-nor-secobaccatin (4) in 76% yield (eq 2). The aldehyde moiety of 4 was then reduced with sodium cyanoborohydride at pH 619 to afford 7-TES-nor-seco baccatin alcohol (5) in 80% yield (eq 2). Finally, 7-TES-nor-secobaccatin alcohol (5) was coupled with N-acyl-3-EEO-~-lactams6 (EE = ethoxyethyl; R = P h or tert-butoxy)20-23 using the new and highly efficient protocol developed in our laboratory21to give novel norseco-taxol (7) and nor-seco-taxotere (8) in fairly good to (15) GuBritte-Voegelein,F.: Gubnard, D.; Lavelle, F.; Le Goff, M. T.; Mangatal, L.; Potier, P. J.Med. Chem. 1991,34,992. (16) Swindell, C. S.;Krauss, N. E. J.Med. Chem. 1991,34, 1176. (17) Appendino, G.; Gariboldi, P.; Gabetta, B.; Pace, R.; Bombardelli, E.; Viterbo, D. J. Chem. SOC.,Perkins Trans. 1 1992, 2925. (18) Appendino, G.; Gariboldi, P.; Gabetta, B.; Bombardelli, E. Fitoterapta-Suppl. a1 N . 1 1993,64, 37. (19) Borch, R. F.; Bernstein, M. D.; Dupont Durst, H. J. Am. Chem. SOC. 1971, 93, 2897. (20) Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun,C. M.; Brigaud, T. Tetrahedron 1992,48,6985.

0022-3263/94/1959-0515$04.50/00 1994 American Chemical Society

Communications

516 J. Org. Chem., Vol. 59, No. 3, 1994

Scheme 1 0

OTES

0

i , ii. i i i __c

7: R = Ph (82%) 8: R = t-BUO (58%)

o

6a: R = P h b R=t-BUO

Key: (i) NaHMDS, THF, -40 "C, 30 min; (ii) 0.5% HCI, 25 "C, 36 h; (iii) TBAF, THF, -10

OC,

5 min.

R

Taxotere@

8 Figure 1. Chem 3D representations of nor-seco-taxotere (8) and taxotere.

-3

TES-CI TEA, OMAP 76%

0

OTES

Gez o h

HO 5

excellent yields (eq 3, Scheme 1). It is worthy of note that the removal of the 7-TES group was not possible under the standard acidic conditions (0.5 ?6 hydrochloric acid in methanol at room temperature for 36 h)" and was only accomplished with the use of tetra-n-butylammonium fluoride (TBAF) in THF at -10 "C for 5 min. The antitumor activities of 7 and 8 were evaluated in

vitro against human ovarian (A121), human non-small cell lung (A549), human colon (HT-29), and human breast (MCF7) cancer cell lines.25 Both nor-seco analogs 7 and 8showed 0.13-0.08pM and0.17-0.10pM level ICmvalues, respectively, which were 20-40 times weaker activities than taxol in the same cell line assay.25 It is worthy of note that 7 and 8 exhibit ICmvalues of 0.47 and 0.36 p M ,respectively, against an adriamycin-resistant human breast cancer (MCF7-R) cell line,%i.e., 7 and 8 are only slightly weaker than the activities of taxol against this particular drugresistant cancer cell. The results obtained in this SAR study clearly indicate the importance of the A-ring for the strong cytotoxicity of taxol and taxotere. However, it is also very important to mention that these two reduced-structure analogsretain a certain level of cytotoxicity. As Figure 1 shows, the conformational analysis of 8 based on molecular modeling (SYBYL6.0) indicates that this nor-seco analog can take

(25) The tumor growth inhibitory activities of 7 and 8 were evaluated agaist human tumor cell lines A121 (ovarian carcinoma), A549 (nonsmall cell lung carcinoma), HT-29 (colon carcinoma), MCF7 (mammary carcinoma), or MCF7-R (mammary carcinoma cells 180 fold resistant to (21) (a)Ojima,I.;Sun,C.M.;Zucco,M.;Park,Y.H.;Duclos,O.;Kuduk, adriamycin) after 72 h drug exposure according to the assay method of S. D.Tetrahedron Lett. 1993,34,4149. For the coupling of 6 with 7-TESSkehan et a1.s ICm values (nM) for 7 and 8 are as follows (the values in baccatin 111, see also: (b) Holton, R. A. Eur. Pat. Appl. E P 400,971,1990. parentheses are for those of Taxol). A121: 7, 117; 8, 131 (6.1). A549: 7, (c) Georg, G. I.; Cheruvallath, 2. S.J. Med. Chem. 1992,35,4230. 133; 8, 169 (3.6). HT-29: 7, 134; 8, 171 (3.2). MCF7: 7, 79; 8, 101 (1.7). (22) Ojima, I.; Zucco, M.; Duclos, 0.; Kuduk, S. D.; Sun, C. M.; Park, MCF7-R 7,471; 8,360 (299). The data represent the mean values of at Y. H. Bioorg. Med. Chem. Lett. 1993,3, 2479. least three separate experiments. (23) Ojima, I.; Habus, I.; Zhao, M.; Georg, G. I.; Jayasinghe, R.J. Org. (26) Skehan, P.; Streng, R.; Scudierok D.;Monks, A.; McMahon, J.; Chem. 1991,56,1681. Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Nat. (24) Denis, J.-N.; Greene, A. E.; Guhnard, D.;Guhritte-Vogelein, F.; Cancer Znst. 1990,82, 1107. Mangatal, L.; Potier, P. J. Am. Chem. SOC.1988, 220,5917. ~~

Communications a folded structure similar to that of taxotere or taxol. However, (i) 8 lacks hydroxyl groups at C-1 and (2-10, (ii) the C-16 methyl is at the concave face (a-face) of the molecule, and (iii) the C-13 side chain conformation is rather flexible. These changesmay account for the reduced cytotoxicity of the novelnor-seco analogs 7 and 8. Further SAR study based on the modification of nor-seco-baccatins 35 is actively underway.

Acknowledgment. This research was supported by a grant from the National Institutes of Health (GM427980). Generous support from the National Cancer Institute (CA

J. Org. Chem., Vol. 59, No. 3, 1994 517 13038) and Indena, SpA is also gratefully acknowledged. The authors are grateful to Dr. Ezio Bombardelli, Indena, SpA for providing them with 14-OH-DAB. One of the authors (1.F.)thanks the Universith di Torino for granting a postdoctoral fellowship for her study at Stony Brook. Supplementary Material Available: Generalexperimental procedures for the synthesesof 3-8 and characterization data for new compounds (4 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.